National Institutes of Health (NIH): Prescription Drug Abuse (R21)

This opportunity uses the R21 Exploratory/Developmental Research Grants funding mechanism.

This Funding Opportunity Announcement (FOA) encourages applicants to develop innovative research applications on prescription drug abuse, including research to examine the factors contributing to prescription drug abuse; to characterise the adverse medical, mental health and social consequences associated with prescription drug abuse; and to develop effective prevention and service delivery approaches and behavioural and pharmacological treatments.

Companion Schemes

Funding & Duration

Direct costs are limited to US $275,000 (approx AUD $380,000) over an R21 two-year period, with no more than US $200,000 (approx AUD $276,000) in direct costs allowed in any single year.

The maximum project period is 2 years.


Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.

Submission Requirements

Further Information

This entry was posted in Arts, Engineering, Computer & Mathematical Sciences, Funding by Award Type, Grants (Project Funds), Health & Medical Sciences, International Funding, Professions, Sciences and tagged . Bookmark the permalink.

Comments are closed.